Q&A: Dr. John Mazziotta on the future of UCLA’s medical school and health system

Earlier in his life, Dr. John C. Mazziotta thought about becoming an architect. With a keen eye for form and function, he would apply his skills to the construction of great buildings. Instead, he chose medicine. Now, after more than 30 years at UCLA — where he has been chair of the department of neurology, an associate vice chancellor and executive vice dean, and founding director of the Ahmanson-Lovelace Brain Mapping Center — that style of visual thinking will serve him well in his new roles as vice chancellor for UCLA Health Sciences, dean of the David Geffen School of Medicine at UCLA and CEO of UCLA Health. “There are many parallels between architecture and construction and what we do in medicine and the building of a large medical enterprise,” he said. “And, on a purely administrative level, it doesn’t hurt to have some interest in the subject when you are managing millions of square feet of space and renovating a giant building. Having some interest and experience about how these things work is helpful.” Mazziotta spoke with U Magazine editor David Greenwald about his new roles and his aspirations for the future of the medical school and health system. As vice chancellor, dean and CEO, you bridge the worlds of the health system and the medical school. How does each of these worlds inform the other? We have one health organization with two big pieces to it: the health system — the hospitals, the clinics, the doctors and n...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news

Related Links:

SMAD4 is the only common SMAD in TGF-β signaling that usually impedes immune cell activation in the tumor microenvironment. However, we demonstrated here that selective deletion of Smad4 in NK cells actually led to dramatically reduced tumor cell rejection and augmented tumor cell metastases, reduced murine CMV clearance, as well as impeded NK cell homeostasis and maturation. This was associated with a downregulation of granzyme B (Gzmb), Kit, and Prdm1 in Smad4-deficient NK cells. We further unveiled the mechanism by which SMAD4 promotes Gzmb expression. Gzmb was identified as a direct target of a transcriptional com...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
The stroma of solid tumors can exclude or limit immune infiltration, or lead to the recruitment of tumor-promoting rather than tumor-attacking immune cells. This finding was reported by Jayaprakash et al. in this issue of the JCI, and it was particularly prominent in the hypoxic zones of tumors in the transgenic adenocarcinoma of the mouse prostate (TRAMP) cancer models. A current clinical goal of immune checkpoint blockade (ICB) is to extend its utility to more patients by converting immunologically “cold” tumors that do not provoke a strong immunological response to “hot” tumors that are invaded b...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Despite the success of immune checkpoint blockade against melanoma, many “cold” tumors like prostate cancer remain unresponsive. We found that hypoxic zones were prevalent across preclinical prostate cancer and resisted T cell infiltration even in the context of CTLA-4 and PD-1 blockade. We demonstrated that the hypoxia-activated prodrug TH-302 reduces or eliminates hypoxia in these tumors. Combination therapy with this hypoxia-prodrug and checkpoint blockade cooperated to cure more than 80% of tumors in the transgenic adenocarcinoma of the mouse prostate–derived (TRAMP-derived) TRAMP-C2 model. Immunofluo...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
The paper, titled 'Debt or Death?', used data on 9.5 million nationally-representative patients between 1998 and 2014, who spend an average of $92,098 a year trying to stay alive.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Source: Peerview CME/CE Video Podcast - Internal Medicine International - Category: Internal Medicine Authors: Tags: Science, Medicine Source Type: video
Conclusion: GSTP1 and CYPs expressions are increased in intracranial tumors. These results should be confirmed with larger series and different enzyme subtypes.
Source: Medical Principles and Practice - Category: Internal Medicine Source Type: research
The start-up ’s optofluidic system could help get personalized cancer cell therapies to more people
Source: Chemical and Engineering News - Category: Chemistry Authors: Source Type: research
Publication date: Available online 15 October 2018Source: European Journal of Surgical OncologyAuthor(s): Han-Yu Deng, Liang Hou, Panpan Zha, Kai-Li Huang, Lei PengAbstractBackgroundWhether sarcopenia has any impact on long-term survival of patients with surgically treated non-small cell lung cancer (NSCLC) remains unclear. We conducted a meta-analysis focusing on current topic comprehensively for the first time.MethodsWe systematically searched relevant studies in PubMed, Embase, and Cochrane Library up to July 3, 2018. Data of 5-year overall survival (OS) and disease-free survival (DFS) rates as well as hazard ratio (HR)...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Three-dimensional mammography screening detected 34 percent more breast cancer tumors than the traditional process of a single image, according to a study.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news
From portable genome sequencers until genetic tests revealing distant relations with Thomas Jefferson, genomics represents a fascinatingly innovative area of healthcare. As the price of genome sequencing has been in free fall for years, the start-up scene is bursting from transformative power. Let’s look at some of the most amazing ventures in genomics! The amazing journey of genome sequencing Genome sequencing has been on an amazing scientific as well as economic journey for the last three decades. The Human Genome Project began in 1990 with the aim of mapping the whole structure of the human genome and sequencing ...
Source: The Medical Futurist - Category: Information Technology Authors: Tags: Genomics Personalized Medicine AI artificial intelligence bioinformatics cancer DNA dna testing DTC gc3 genetic disorders genetics genome sequencing personal genomics precision medicine Source Type: blogs
More News: Academia | Allergy & Immunology | Biomedical Science | Brain | Brain Cancers | Breast Cancer | Breast Needle Aspiration | Cancer | Cancer & Oncology | Cancer Therapy | Cardiology | Cardiovascular | Childhood Cancer | Cholesterol | Clinical Trials | Computers | Education | Environmental Health | Food and Drug Administration (FDA) | Funding | Gastroschisis Repair | Genetics | Graduation | Health | Health Management | Heart | Hospitals | Jobs | Learning | Lessons | Lung Cancer | Melanoma | Men | Neurology | Neuroscience | Nurses | Nursing | Partnerships | Science | Skin Cancer | Strategic Planning | Students | Training | Universities & Medical Training